In the evolving landscape of radiation oncology, the discussion around supervision models—direct or virtual—presents a pivotal moment for the field. This debate not only impacts patient access and safety but also stresses upon the profession’s adaptability in integrating technology while preserving core clinical standards.

In the evolving landscape of colorectal cancer screening, recent evidence suggests a critical reevaluation of the benefits and risks of routine surveillance colonoscopies in patients over 70, emphasizing the importance of individualized patient care.

In a recent phase 2–3 trial, nirmatrelvir–ritonavir did not significantly shorten the time to COVID-19 symptom resolution compared to placebo, yet it demonstrated a trend towards reduced hospitalization and death rates, emphasizing the importance of tailored treatment strategies.

Imetelstat has shown promising results in improving the quality of life for MDS patients by significantly reducing transfusion dependency, a critical consideration in the management of this blood disorder.

SGLT-2 inhibitors have emerged as a cornerstone in managing HFrEF and CKD, demonstrating substantial reductions in cardiovascular and renal adverse outcomes. This class of medications is reshaping the therapeutic approach in patients with these comorbid conditions, providing a dual benefit that was once considered challenging to achieve.

This study reinforces the noninferiority of sentinel node biopsy in patients with clinically node-negative breast cancer, offering a potential paradigm shift in surgical decision-making and patient care.